Fundación Investigación Clínico de Valencia.
Welcome,         Profile    Billing    Logout  
 0 Trials 
4 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Fidalgo, Alejandro Pérez
RAMP 301, NCT06072781: A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer

Recruiting
3
270
Europe, Canada, US, RoW
avutometinib, avutometinib (VS-6766), Defactinib, defactinib (VS-6063), Pegylated liposomal doxorubicin, Caelyx, Doxil, Lipodox, Paclitaxel, Nov-Onxol, Onxol, Navaplus, Taxol, Letrozole, Femara, Anastrozole, Arimidex
Verastem, Inc., GOG Foundation, European Network of Gynaecological Oncological Trial Groups (ENGOT), Australia New Zealand Gynaecological Oncology Group
Low Grade Serous Ovarian Cancer
10/28
02/31
NIRVANA-1, NCT05183984 / 2021-004278-76: Niraparib with BeVAcizumab After Complete CytoreductioN in Patients with OvArian Cancer

Recruiting
2
390
Europe, Japan, RoW
Chemotherapy, Bevacizumab-Awwb, Niraparib
ARCAGY/ GINECO GROUP, GSK
Ovarian Cancer
02/27
02/30
SeliSarc, NCT06114004: Selinexor Plus Gemcitabine in Selected Advanced Soft-tissue Sarcoma

Recruiting
2
88
Europe
Selinexor 20 MG, KPT-330, Gemcitabine
Asociación Europea y Latinoamericana SELNET para la Investigación en Sarcomas
Sarcoma,Soft Tissue
05/26
05/26
ImmunoSarc, NCT03277924 / 2016-004040-10: Trial of Sunitinib and/or Nivolumab Plus Chemotherapy in Advanced Soft Tissue and Bone Sarcomas

Completed
1/2
197
Europe
Sunitinib 37.5 MG, Sunitinib 25 MG [Sutent], Sutent, Nivolumab 100 MG/10 ML [Opdivo], Opdivo, Epirubicin, Ifosfamide, Doxorubicin, Dacarbazine, Cisplatin, Methotrexate
Grupo Espanol de Investigacion en Sarcomas
Soft Tissue Sarcoma, Bone Sarcoma
06/24
06/24
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Fidalgo, Alejandro Pérez
RAMP 301, NCT06072781: A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer

Recruiting
3
270
Europe, Canada, US, RoW
avutometinib, avutometinib (VS-6766), Defactinib, defactinib (VS-6063), Pegylated liposomal doxorubicin, Caelyx, Doxil, Lipodox, Paclitaxel, Nov-Onxol, Onxol, Navaplus, Taxol, Letrozole, Femara, Anastrozole, Arimidex
Verastem, Inc., GOG Foundation, European Network of Gynaecological Oncological Trial Groups (ENGOT), Australia New Zealand Gynaecological Oncology Group
Low Grade Serous Ovarian Cancer
10/28
02/31
NIRVANA-1, NCT05183984 / 2021-004278-76: Niraparib with BeVAcizumab After Complete CytoreductioN in Patients with OvArian Cancer

Recruiting
2
390
Europe, Japan, RoW
Chemotherapy, Bevacizumab-Awwb, Niraparib
ARCAGY/ GINECO GROUP, GSK
Ovarian Cancer
02/27
02/30
SeliSarc, NCT06114004: Selinexor Plus Gemcitabine in Selected Advanced Soft-tissue Sarcoma

Recruiting
2
88
Europe
Selinexor 20 MG, KPT-330, Gemcitabine
Asociación Europea y Latinoamericana SELNET para la Investigación en Sarcomas
Sarcoma,Soft Tissue
05/26
05/26
ImmunoSarc, NCT03277924 / 2016-004040-10: Trial of Sunitinib and/or Nivolumab Plus Chemotherapy in Advanced Soft Tissue and Bone Sarcomas

Completed
1/2
197
Europe
Sunitinib 37.5 MG, Sunitinib 25 MG [Sutent], Sutent, Nivolumab 100 MG/10 ML [Opdivo], Opdivo, Epirubicin, Ifosfamide, Doxorubicin, Dacarbazine, Cisplatin, Methotrexate
Grupo Espanol de Investigacion en Sarcomas
Soft Tissue Sarcoma, Bone Sarcoma
06/24
06/24

Download Options